Amgen Inc (AMGN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 2, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AMGN SEC filings page.
Amgen Inc (AMGN) reported $38.1B in revenue over the twelve months to Jun 30, 2026, up 9.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Margin recovery and debt reduction returned Amgen to stronger earnings in FY2025, while reinvestment restrained free cash flow.
The operating rebound was more cash-intensive than the income statement suggests: operating margin improved from21.7% to24.7% , yet free-cash-flow margin fell from31.1% to22.0% . That combination indicates that improved profitability did not translate proportionally into distributable cash because capital spending absorbed more operating cash.
Gross margin recovered from
The balance sheet became less debt-dependent: debt-to-equity declined from 9.6x to 5.8x as equity increased, but the current ratio narrowed from 1.3x to 1.1x. Amgen therefore reduced longer-term leverage while retaining a thinner short-term liquidity cushion, and financing cash outflows of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Amgen Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Amgen Inc has an operating margin of 24.7%, meaning the company retains $25 of operating profit per $100 of revenue. This strong profitability earns a score of 87/100, reflecting efficient cost management and pricing power. This is up from 21.7% the prior year.
Amgen Inc's revenue grew 10.0% year-over-year to $36.8B, a solid pace of expansion. This earns a growth score of 74/100.
Amgen Inc has elevated debt relative to equity (D/E of 5.78), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 23/100, reflecting increased financial risk.
Amgen Inc's current ratio of 1.14 is below the typical benchmark, resulting in a score of 26/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Amgen Inc converts 22.0% of revenue into free cash flow ($8.1B). This strong cash generation earns a score of 91/100.
Amgen Inc earns a strong 89.1% return on equity (ROE), meaning it generates $89 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 74/100. This is up from 69.6% the prior year.
Amgen Inc scores 1.99, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($217.9B) relative to total liabilities ($81.9B). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Amgen Inc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Amgen Inc generates $1.29 in operating cash flow ($10.0B OCF vs $7.7B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Amgen Inc earns $3.30 in operating income for every $1 of interest expense ($9.1B vs $2.8B). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Amgen Inc generated $10.1B in revenue in Q2 2026. This represents an increase of 9.5% from the same quarter a year earlier. Against the prior quarter it is up 16.7%.
Amgen Inc's EBITDA was $3.7B in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 29.9% from the same quarter a year earlier. Against the prior quarter it is down 1.2%.
Amgen Inc reported $2.4B in net income in Q2 2026. This represents an increase of 65.9% from the same quarter a year earlier. Against the prior quarter it is up 30.6%.
Amgen Inc earned $4.37 per diluted share (EPS) in Q2 2026. This represents an increase of 64.9% from the same quarter a year earlier. Against the prior quarter it is up 30.8%.
Cash & Balance Sheet
Amgen Inc generated $3.5B in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 82.6% from the same quarter a year earlier. Against the prior quarter it is up 136.2%.
Amgen Inc held $14.0B in cash against $51.9B in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Amgen Inc's gross margin was 72.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 4.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.9 percentage points.
Amgen Inc's operating margin was 34.9% in Q2 2026, reflecting core business profitability. This is up 6.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.0 percentage points.
Amgen Inc's net profit margin was 23.6% in Q2 2026, showing the share of revenue converted to profit. This is up 8.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.5 percentage points.
Amgen Inc's ROE was 20.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 1.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.
Capital Allocation
Amgen Inc invested $1.9B in research and development in Q2 2026. This represents an increase of 7.1% from the same quarter a year earlier. Against the prior quarter it is up 8.7%.
Amgen Inc invested $513.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 39.0% from the same quarter a year earlier. Against the prior quarter it is down 27.9%.
Not reported for Q2 2026.
AMGN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.1B+9.5% | $8.6B+5.8% | $9.9B+8.6% | $9.6B+12.4% | $9.2B+9.4% | $8.1B+9.4% | $9.1B+10.9% | $8.5B+23.2% |
| Cost of Revenue | $2.8B-6.6% | $2.7B-7.5% | $3.0B-4.4% | $3.1B-6.9% | $3.0B-7.0% | $3.0B-7.2% | $3.1B0.0% | $3.3B+83.3% |
| Gross Profit | $7.2B+17.4% | $5.9B+13.4% | $6.9B+15.3% | $6.5B+24.7% | $6.2B+19.7% | $5.2B+22.0% | $6.0B+17.5% | $5.2B+1.9% |
| R&D Expenses | $1.9B+7.1% | $1.7B+15.7% | $2.1B+24.2% | $1.9B+31.0% | $1.7B+20.5% | $1.5B+10.6% | $1.7B+12.4% | $1.4B+34.4% |
| SG&A Expenses | $1.7B+3.2% | $1.6B-5.0% | $2.0B+3.9% | $1.7B+5.8% | $1.7B-5.3% | $1.7B-6.7% | $1.9B-17.4% | $1.6B+20.1% |
| Operating Income | $3.5B+32.3% | $2.7B+126.3% | $2.7B+17.7% | $2.5B+23.4% | $2.7B+39.1% | $1.2B+18.9% | $2.3B+81.8% | $2.0B+1.3% |
| EBITDA | $3.7B+29.9% | $3.8B+47.4% | $6.0B-0.9% | $2.8B+22.9% | $2.9B+36.2% | $2.6B+7.3% | $6.1B+130.3% | $2.2B-23.0% |
| Interest Expense | $673.0M-3.0% | $657.0M-9.1% | $653.0M-12.6% | $685.0M-11.7% | $694.0M-14.1% | $723.0M-12.3% | $747.0M-9.0% | $776.0M+2.2% |
| Income Tax | $393.0M+189.0% | $265.0M+9.1% | $181.0M+16.8% | $705.0M+160.1% | $136.0M+183.3% | $243.0M+440.0% | $155.0M+82.4% | $271.0M+24.9% |
| Net Income | $2.4B+65.9% | $1.8B+5.1% | $1.3B+112.6% | $3.2B+13.6% | $1.4B+92.0% | $1.7B+1631.0% | $627.0M-18.3% | $2.8B+63.6% |
| EPS (Basic) | $4.40+65.4% | $3.37+4.7% | $2.47+111.1% | $5.98+13.5% | $2.66+91.4% | $3.22+1633.3% | $1.17-18.8% | $5.27+63.2% |
| EPS (Diluted) | $4.37+64.9% | $3.34+4.4% | $2.46+112.1% | $5.93+13.6% | $2.65+92.0% | $3.20+1623.8% | $1.16-18.9% | $5.22+62.1% |
| Diluted Shares (Avg) | 544M+0.6% | 544M+0.6% | N/A | 542M0.0% | 541M0.0% | 541M+0.9% | N/A | 542M+0.7% |
AMGN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $95.6B+8.8% | $92.5B+3.5% | $90.6B-1.4% | $90.1B-0.8% | $87.9B-3.3% | $89.4B-3.9% | $91.8B-5.5% | $90.9B+0.4% |
| Current Assets | $35.0B+30.8% | $31.5B+16.9% | $29.1B+0.1% | $27.9B+4.2% | $26.7B-1.7% | $26.9B-3.9% | $29.0B-4.3% | $26.8B-44.8% |
| Cash & Equivalents | $14.0B+74.3% | $12.0B+36.6% | $9.1B-23.8% | $9.4B+4.8% | $8.0B-13.7% | $8.8B-9.3% | $12.0B+9.4% | $9.0B-74.1% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $6.2B-5.5% | $6.2B-8.1% | $6.2B-11.0% | $6.3B-13.8% | $6.6B-17.7% | $6.7B-22.9% | $7.0B-26.5% | $7.4B+46.5% |
| Accounts Receivable | $10.2B+17.5% | $9.1B+12.4% | $9.6B+41.1% | $8.5B+16.0% | $8.7B+25.5% | $8.1B+20.0% | $6.8B-6.7% | $7.3B+19.1% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $18.7B0.0% | $18.7B+0.2% | $18.7B+0.2% | $18.7B+0.1% | $18.7B+0.3% | $18.6B+0.4% | $18.6B0.0% | $18.7B+20.3% |
| Total Liabilities | $84.0B+4.3% | $83.3B+0.2% | $81.9B-4.7% | $80.5B-3.4% | $80.5B-5.3% | $83.2B-5.5% | $86.0B-5.5% | $83.4B+0.6% |
| Current Liabilities | $25.5B+24.5% | $25.0B+8.5% | $25.5B+10.3% | $21.8B+7.3% | $20.5B-4.8% | $23.0B+16.7% | $23.1B+25.6% | $20.3B+19.8% |
| Non-Current Liabilities | $58.4B-2.6% | $58.4B-3.0% | $56.4B-10.2% | $58.7B-6.8% | $60.0B-5.5% | $60.2B-11.9% | $62.9B-13.3% | $63.0B-4.4% |
| Long-Term Debt | $51.9B-3.5% | $51.9B-3.9% | $50.0B-11.6% | $52.4B-7.8% | $53.8B-5.9% | $54.0B-10.1% | $56.5B-10.5% | $56.9B-3.7% |
| Total Equity | $11.7B+57.4% | $9.2B+48.1% | $8.7B+47.3% | $9.6B+27.8% | $7.4B+25.4% | $6.2B+23.6% | $5.9B-5.7% | $7.5B-1.7% |
| Retained Earnings | -$22.3B+13.4% | -$24.6B+9.2% | -$25.1B+9.0% | -$23.8B+6.8% | -$25.7B+5.2% | -$27.1B+2.6% | -$27.6B-3.9% | -$25.5B-2.2% |
AMGN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.0B+75.5% | $2.2B+57.4% | $1.6B-66.4% | $4.7B+31.2% | $2.3B-7.3% | $1.4B+101.9% | $4.8B+786.8% | $3.6B+29.4% |
| Depreciation & Amortization | $222.0M+0.9% | $1.1B-19.5% | $1.1B-19.0% | $232.0M+17.2% | $220.0M+8.9% | $1.4B-0.9% | $1.4B+1.2% | $198.0M-77.9% |
| Stock-Based Compensation | N/A | $75.0M-11.8% | N/A | N/A | N/A | $85.0M-17.5% | N/A | N/A |
| Capital Expenditures | $513.0M+39.0% | $712.0M+73.2% | $642.0M+73.0% | $436.0M+69.6% | $369.0M+55.0% | $411.0M+78.7% | $371.0M+49.0% | $257.0M+3.6% |
| Free Cash Flow | $3.5B+82.6% | $1.5B+50.7% | $961.0M-78.2% | $4.2B+28.2% | $1.9B-14.0% | $980.0M+113.5% | $4.4B+1422.5% | $3.3B+31.9% |
| Investing Cash Flow | -$569.0M-46.3% | -$716.0M-60.2% | -$693.0M-72.4% | -$414.0M-97.1% | -$389.0M-79.3% | -$447.0M-106.0% | -$402.0M+98.5% | -$210.0M+19.8% |
| Financing Cash Flow | -$1.5B+44.6% | $1.4B+135.0% | -$1.2B+12.9% | -$2.9B+21.9% | -$2.7B-0.9% | -$4.1B-140.5% | -$1.4B-151.1% | -$3.7B-82.1% |
| Dividends Paid | $1.4B+6.4% | $1.4B+6.2% | $1.3B+6.5% | $1.3B+6.0% | $1.3B+5.9% | $1.3B+5.9% | $1.2B+5.7% | $1.2B+6.1% |
Not reported in any period shown, so not listed: Share Buybacks.
AMGN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.0%+4.8pp | 68.2%+4.6pp | 69.8%+4.1pp | 67.8%+6.7pp | 67.2%+5.8pp | 63.6%+6.6pp | 65.8%+3.7pp | 61.1%-12.8pp |
| Operating Margin | 34.9%+6.0pp | 30.9%+16.5pp | 27.6%+2.1pp | 26.4%+2.4pp | 28.9%+6.2pp | 14.5%+1.2pp | 25.4%+9.9pp | 24.1%-5.2pp |
| Net Margin | 23.6%+8.0pp | 21.1%-0.1pp | 13.5%+6.6pp | 33.7%+0.4pp | 15.6%+6.7pp | 21.2%+22.7pp | 6.9%-2.5pp | 33.3%+8.2pp |
| Return on Equity | 20.3%+1.0pp | 19.8%-8.1pp | 15.4%+4.7pp | 33.4%-4.2pp | 19.3%+6.7pp | 27.9%+30.1pp | 10.7%-1.6pp | 37.6%+15.0pp |
| Return on Assets | 2.5%+0.9pp | 2.0%0.0pp | 1.5%+0.8pp | 3.6%+0.5pp | 1.6%+0.8pp | 1.9%+2.1pp | 0.7%-0.1pp | 3.1%+1.2pp |
| Current Ratio | 1.37+0.1x | 1.26+0.1x | 1.14-0.1x | 1.280.0x | 1.310.0x | 1.17-0.3x | 1.26-0.4x | 1.32-1.5x |
| Debt-to-Equity | 4.44-2.8x | 5.65-3.1x | 5.78-3.8x | 5.45-2.1x | 7.24-2.4x | 8.70-3.3x | 9.62-0.5x | 7.55-0.2x |
| Asset Turnover | 0.110.0x | 0.090.0x | 0.110.0x | 0.110.0x | 0.100.0x | 0.090.0x | 0.100.0x | 0.090.0x |
| FCF Margin | 34.7%+13.9pp | 17.1%+5.1pp | 9.7%-38.7pp | 44.5%+5.5pp | 20.8%-5.7pp | 12.0%+5.9pp | 48.4%+44.9pp | 39.0%+2.6pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Amgen Inc AMGN | FY2025 | $36.8B | $7.7B | 21.0% | $217.9B | 63/100 |
| Gilead Sciences Inc GILD | FY2025 | $29.4B | $8.5B | 28.9% | $184.8B | 64/100 |
| Pfizer Inc. PFE | FY2025 | $62.6B | $7.8B | 12.4% | $162.6B | 33/100 |
| Bristol-Myers Squibb Co. BMY | FY2025 | $48.2B | $7.1B | 14.6% | $127.5B | 33/100 |
Where Amgen Inc Ranks
Frequently Asked Questions
What is Amgen Inc's annual revenue?
Amgen Inc (AMGN) reported $36.8B in total revenue for fiscal year 2025. This represents a 10.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Amgen Inc's revenue growing?
Amgen Inc (AMGN) revenue grew by 10.0% year-over-year, from $33.4B to $36.8B in fiscal year 2025.
Is Amgen Inc profitable?
Yes, Amgen Inc (AMGN) reported a net income of $7.7B in fiscal year 2025, with a net profit margin of 21.0%.
What is Amgen Inc's EBITDA?
Amgen Inc (AMGN) had EBITDA of $14.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Amgen Inc have?
As of fiscal year 2025, Amgen Inc (AMGN) had $9.1B in cash and equivalents against $50.0B in long-term debt.
What is Amgen Inc's gross margin?
Amgen Inc (AMGN) had a gross margin of 67.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Amgen Inc's operating margin?
Amgen Inc (AMGN) had an operating margin of 24.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Amgen Inc's net profit margin?
Amgen Inc (AMGN) had a net profit margin of 21.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Amgen Inc pay dividends?
Yes, Amgen Inc (AMGN) paid $9.66 per share in dividends during fiscal year 2025.
What is Amgen Inc's return on equity (ROE)?
Amgen Inc (AMGN) has a return on equity of 89.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Amgen Inc's free cash flow?
Amgen Inc (AMGN) generated $8.1B in free cash flow during fiscal year 2025. This represents a -22.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Amgen Inc's operating cash flow?
Amgen Inc (AMGN) generated $10.0B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Amgen Inc's total assets?
Amgen Inc (AMGN) had $90.6B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Amgen Inc's capital expenditures?
Amgen Inc (AMGN) invested $1.9B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Amgen Inc spend on research and development?
Amgen Inc (AMGN) invested $7.3B in research and development during fiscal year 2025.
What is Amgen Inc's current ratio?
Amgen Inc (AMGN) had a current ratio of 1.14 as of fiscal year 2025, which is considered adequate.
What is Amgen Inc's debt-to-equity ratio?
Amgen Inc (AMGN) had a debt-to-equity ratio of 5.78 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Amgen Inc's return on assets (ROA)?
Amgen Inc (AMGN) had a return on assets of 8.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Amgen Inc's P/E ratio?
Amgen Inc (AMGN) trades at 24.9x earnings, its market capitalization divided by net income of $8.7B net income, trailing 12 months to June 30, 2026. The market capitalization is $217.9B as of Oct 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Amgen Inc's price-to-sales ratio?
Amgen Inc (AMGN) trades at 5.7x sales, its market capitalization divided by revenue of $38.1B revenue, trailing 12 months to June 30, 2026. The market capitalization is $217.9B as of Oct 2, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Amgen Inc's Altman Z-Score?
Amgen Inc (AMGN) has an Altman Z-Score of 1.99, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Amgen Inc's Piotroski F-Score?
Amgen Inc (AMGN) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Amgen Inc's earnings high quality?
Amgen Inc (AMGN) has an earnings quality ratio of 1.29x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Amgen Inc cover its interest payments?
Amgen Inc (AMGN) has an interest coverage ratio of 3.30x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Amgen Inc?
Amgen Inc (AMGN) scores 63 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.